Takeda explores $1B-plus sale of chemicals stake: Bloomberg

Takeda is finally on the up-and-up after posting growth in its last fiscal year. And to help keep that growth coming, it’s exploring an asset sale to drum up cash.

The Japanese drugmaker is considering selling off its majority, 72% stake in chemicals business Wako Pure Chemical Industries Ltd., a transaction that could bring in more than $1 billion, sources tell Bloomberg. It’s working with advisers at Nomura Holdings on a divestment, which could attract interest from companies such as Fujifilm and private equity outfits including Permira Advisers and Carlyle Group.

If Takeda does decide to sell, “it seems like they can sell at a premium,” Iwai Cosmo Securities analyst Kazuyoshi Saito told the news service. “They will be able to divert funds to businesses they prioritize, such as oncology and gastrointestinal areas.”

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Oncology and GI are areas where Takeda has newcomer drugs that boosted the pharma in its last fiscal year, ended in March. Ulcerative colitis and Crohn’s disease med Entyvio and multiple myeloma drug Ninlaro weathered hefty competition to chip in revenue that pushed Takeda’s total up 1.7% for the year. Entyvio, in particular, came up big, spurring a 23.6% year-over-year sales leap for the company’s GI portfolio.

And Takeda is counting on those therapies to keep the revenue expansion coming. In May, it guided to sales growth in the mid-single-digits range, as well as underlying core earnings and underlying core EPS expansion in the low- to mid-teens.

If the company does pull off a Wako sale, it wouldn’t be the first time lately that it jettisoned a non-core asset. Last year, Takeda agreed to hand its respiratory business to AstraZeneca ($AZN) for $575 million.

And as far as that trend goes, it’s certainly not alone among its pharma peers. Plenty of other drugmakers have sold off or are looking to dispose of meds and units that don’t fit in with the rest of their portfolio or aren’t critical to their top lines--including Valeant ($VRX), whose new CEO Joseph Papa says the company is pursuing transactions that could help make its business less complex. AstraZeneca has been particularly aggressive in this realm, having raised some billions of dollars in the last few years by selling off assets it calls non-core. In June, for example, it off-loaded an anesthetics portfolio to Aspen Pharmacare for up to $770 million. 

- get more from Bloomberg 

Related Articles:
Reorg, new meds help Takeda crawl out of profit hole
Takeda dumps weight loss med Contrave, leaving Orexigen in the lurch
New CEO Weber deals with Takeda's loss and promises brighter future
Takeda will grow again in the coming year, COO Weber promises
Second-line use, crowded market won't keep Takeda's Entyvio from blockbuster run
AstraZeneca is once again trading off old meds for new cash. The U.K.-based drugmaker

AstraZeneca gins up $520M-plus selling anesthetics rights to Aspen

Read more on

Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.